CB2 Insights, a leading data-driven company focused on bringing Real-World Evidence driven from the point-of-care to the medical cannabis community, announced that it has been selected as exclusive research technology platform for the leading, and only, independent scientific body on drugs in the UK, working to provide evidence-based information on safety and efficacy within medical cannabis. A Letter of Intent has been signed between CB2 and Drug Science.
CB2 Insights will also join the Drug Science working group, which is led by Drug Science, patient organisations, academia and industry leaders
including Licensed Producers Althea, Cannuba and Alta Flora. CB2 and the working group aims to create the UK’s only independent GDPR-compliant database of patient health data focused on assessing the health-related outcomes of patients suffering from chronic pain, PTSD, multiple sclerosis, Tourette’s syndrome and other indications after the integration of medical cannabis therapy into (or as a replacement for) traditional treatment regimens.
Read the full release here